View Item 

Show simple item record

A Double‐Blind Randomized Placebo‐Controlled Trial of Oral Naltrexone for Heavy‐Drinking Smokers Seeking Smoking Cessation Treatment
dc.contributor.authorKahler, Christopher W.
dc.contributor.authorCioe, Patricia A.
dc.contributor.authorTzilos, Golfo K.
dc.contributor.authorSpillane, Nichea S.
dc.contributor.authorLeggio, Lorenzo
dc.contributor.authorRamsey, Susan E.
dc.contributor.authorBrown, Richard A.
dc.contributor.authorO’Malley, Stephanie S.
dc.date.accessioned2017-06-16T20:09:58Z
dc.date.available2018-08-07T15:51:22Zen
dc.date.issued2017-06
dc.identifier.citationKahler, Christopher W.; Cioe, Patricia A.; Tzilos, Golfo K.; Spillane, Nichea S.; Leggio, Lorenzo; Ramsey, Susan E.; Brown, Richard A.; O’Malley, Stephanie S. (2017). "A Double‐Blind Randomized Placebo‐Controlled Trial of Oral Naltrexone for Heavy‐Drinking Smokers Seeking Smoking Cessation Treatment." Alcoholism: Clinical and Experimental Research 41(6): 1201-1211.
dc.identifier.issn0145-6008
dc.identifier.issn1530-0277
dc.identifier.urihttps://hdl.handle.net/2027.42/137315
dc.publisherAmerican Psychiatric Association
dc.publisherWiley Periodicals, Inc.
dc.subject.otherNaltrexone
dc.subject.otherAlcohol Dependence
dc.subject.otherSmoking Cessation
dc.subject.otherHeavy Drinking
dc.titleA Double‐Blind Randomized Placebo‐Controlled Trial of Oral Naltrexone for Heavy‐Drinking Smokers Seeking Smoking Cessation Treatment
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137315/1/acer13396.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/137315/2/acer13396_am.pdf
dc.identifier.doi10.1111/acer.13396
dc.identifier.sourceAlcoholism: Clinical and Experimental Research
dc.identifier.citedreferenceRukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, Lerman C ( 2005 ) Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology 180: 41 – 48.
dc.identifier.citedreferenceMorgenstern J, Kuerbis AN, Chen AC, Kahler CW, Bux DA JR, Kranzler HR ( 2012 ) A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men. J Consult Clin Psychol 80: 863 – 875.
dc.identifier.citedreferenceMurray RP, Istvan JA, Voelker HT, Rigdon MA, Wallace MD ( 1995 ) Level of involvement with alcohol and success at smoking cessation in the lung health study. J Stud Alcohol 56: 74 – 82.
dc.identifier.citedreferenceO’Malley SS, Corbin WR, Leeman RF, Demartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR ( 2015 ) Reduction of alcohol drinking in young adults by naltrexone: a double‐blind, placebo‐controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry 76: e207 – e213.
dc.identifier.citedreferenceO’Malley SS, Krishnan‐Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW ( 2009 ) Dose‐dependent reduction of hazardous alcohol use in a placebo‐controlled trial of naltrexone for smoking cessation. Int J Neuropsychopharmacol 12: 589 – 597.
dc.identifier.citedreferencePettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ ( 2004 ) RE: COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. DHHS Publication No (NIH)04‐5289, Bethesda, MD.
dc.identifier.citedreferenceRay LA, Miranda R Jr, Kahler CW, Leventhal AM, Monti PM, Swift R, Hutchison KE ( 2007 ) Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology 193: 449 – 456.
dc.identifier.citedreferenceRoche DJ, King AC ( 2015 ) Sex differences in acute hormonal and subjective response to naltrexone: the impact of menstrual cycle phase. Psychoneuroendocrinology 52: 59 – 71.
dc.identifier.citedreferenceRohsenow DJ, Monti PM, Hutchison KE, Swift RM, Mackinnon SV, Sirota AD, Kaplan GB ( 2007 ) High‐dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol 15: 81 – 92.
dc.identifier.citedreferenceSAS Institute Inc ( 2012 ) SAS 9.4. for Windows [Computer software], SAS, Cary, NC.
dc.identifier.citedreferenceSchroder H, Marrugat J, Elosua R, Covas MI ( 2002 ) Tobacco and alcohol consumption: impact on other cardiovascular and cancer risk factors in a southern European Mediterranean population. Br J Nutr 88: 273 – 281.
dc.identifier.citedreferenceShiffman S, Paty JA, Gnys M, Kassel JA, Hickcos M ( 1996 ) First lapses to smoking: within‐subjects analysis of real‐time reports. J Consult Clin Psychol 64: 366 – 379.
dc.identifier.citedreferenceSmith PM, Kraemer HC, Miller NH, Debusk RF, Taylor CB ( 1999 ) In‐hospital smoking cessation programs: Who responds, who doesn’t? J Consult Clin Psychol 67: 19 – 27.
dc.identifier.citedreferenceSobell LC, Sobell MB ( 1996 ) Timeline Followback: A Calendar Method for Assessing Alcohol and Drug Use. Addiction Research Foundation, Toronto, ON, Canada.
dc.identifier.citedreferenceSRNT Subcommittee on Biochemical Verification ( 2002 ) Biochemical verification of tobacco use and cessation. Nicotine Tob Res 4: 149 – 159.
dc.identifier.citedreferenceStead LF, Koilpillai P, Fanshawe TR, Lancaster T ( 2016 ) Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev ( 3 ): CD008286.
dc.identifier.citedreferenceStead LF, Perera R, Bullen C, Mant D, Hartmann‐Boyce J, Cahill K, Lancaster T ( 2012 ) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev ( 11 ): CD000146.
dc.identifier.citedreferenceSullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM ( 1989 )  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar). Br J Addict 84: 1353 – 1357.
dc.identifier.citedreferenceSutherland G, Stapleton JA, Russell MA, Feyerabend C ( 1995 ) Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology 120: 418 – 425.
dc.identifier.citedreferenceSwift R, Oslin DW, Alexander M, Forman R ( 2011 ) Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 72: 1012 – 1018.
dc.identifier.citedreferenceToll BA, Cummings KM, O’Malley SS, Carlin‐Menter S, McKee SA, Hyland A, Wu R, Hopkins J, Celestino P ( 2012 ) Tobacco quitlines need to assess and intervene with callers’ hazardous drinking. Alcohol Clin Exp Res 36: 1653 – 1658.
dc.identifier.citedreferenceToll BA, Martino S, O’Malley SS, Fucito LM, McKee SA, Kahler CW, Rojewski AM, Mahoney MC, Wu R, Celestino P, Seshadri S, Koutsky J, Hyland A, Cummings KM ( 2015 ) A randomized trial for hazardous drinking and smoking cessation for callers to a quitline. J Consult Clin Psychol 83: 445 – 454.
dc.identifier.citedreferenceWei I ( 1978 ) Application of an urn model to the design of sequential controlled clinical trials. J Am Stat Assoc 73: 559 – 563.
dc.identifier.citedreferenceYardley MM, Mirbaba MM, Ray LA ( 2015 ) Pharmacological options for smoking cessation in heavy‐drinking smokers. CNS Drugs 29: 833 – 845.
dc.identifier.citedreferenceZeger SL, Liang K‐Y ( 1986 ) Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42: 121 – 130.
dc.identifier.citedreferenceAmerican Psychiatric Association ( 1994 ) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DC.
dc.identifier.citedreferenceAugustson EM, Wanke KL, Rogers S, Bergen AW, Chatterjee N, Synder K, Albanes D, Taylor PR, Caporaso NE ( 2008 ) Predictors of sustained smoking cessation: a prospective analysis of chronic smokers from the alpha‐tocopherol beta‐carotene cancer prevention study. Am J Public Health 98: 549 – 555.
dc.identifier.citedreferenceBaer JS, Lichtenstein E ( 1988 ) Classification and prediction of smoking relapse episodes: an exploration of individual differences. J Consult Clin Psychol 56: 104 – 110.
dc.identifier.citedreferenceBorland R ( 1990 ) Slip‐ups and relapse in attempts to quit smoking. Addict Behav 15: 235 – 245.
dc.identifier.citedreferenceBrown RA, Abrantes AM, Strong DR, Niaura R, Kahler CW, Miller IW, Price LH ( 2014 ) Efficacy of sequential use of fluoxetine for smoking cessation in elevated depressive symptom smokers. Nicotine Tob Res 16: 197 – 207.
dc.identifier.citedreferenceBrown RA, Burgess ES, Sales SD, Whiteley JA, Evans DM, Miller IW ( 1998 ) Reliability and validity of a smoking timeline follow‐back interview. Psychol Addict Behav 12: 101 – 112.
dc.identifier.citedreferenceCook JW, Fucito LM, Piasecki TM, Piper ME, Schlam TR, Berg KM, Baker TB ( 2012 ) Relations of alcohol consumption with smoking cessation milestones and tobacco dependence. J Consult Clin Psychol 80: 1075 – 1085.
dc.identifier.citedreferenceCropsey KL, Trent LR, Clark CB, Stevens EN, Lahti AC, Hendricks PS ( 2014 ) How low should you go? Determining the optimal cutoff for exhaled carbon monoxide to confirm smoking abstinence when using cotinine as reference. Nicotine Tob Res 16: 1348 – 1355.
dc.identifier.citedreferenceDollar KM, Homish GG, Kozlowski LT, Leonard KE ( 2009 ) Spousal and alcohol‐related predictors of smoking cessation: a longitudinal study in a community sample of married couples. Am J Public Health 99: 231 – 233.
dc.identifier.citedreferenceEbbert JO, Janney CA, Sellers TA, Folsom AR, Cerhan JR ( 2005 ) The association of alcohol consumption with coronary heart disease mortality and cancer incidence varies by smoking history. J Gen Intern Med 20: 14 – 20.
dc.identifier.citedreferenceEpperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley SS ( 2010 ) Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend 112: 1 – 8.
dc.identifier.citedreferenceEpstein AM, King AC ( 2004 ) Naltrexone attenuates acute cigarette smoking behavior. Pharmacol Biochem Behav 77: 29 – 37.
dc.identifier.citedreferenceFiore MC, Jaén C, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF ( 2008 ) Treating Tobacco Use and Dependence: 2008 Update. U.S. Department of Health and Human Services, Public Health Service, Rockville, MD.
dc.identifier.citedreferenceFirst MB, Spitzer RL, Gibbon M, Williams JBW ( 1995 ) Structured Clinical Interview for DSM‐IV Axis I Disorders. New York State Psychiatric Institute, New York, NY.
dc.identifier.citedreferenceFridberg DJ, Cao D, Grant JE, King AC ( 2014 ) Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcohol Clin Exp Res 38: 2622 – 2629.
dc.identifier.citedreferenceGarbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov‐Polevoy A, Jordan HS, Bobashev GV ( 2014 ) Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 109: 1274 – 1284.
dc.identifier.citedreferenceGossop M, Keaney F, Stewart D, Marshall EJ, Strang J ( 2002 ) A Short Alcohol Withdrawal Scale (SAWS): development and psychometric properties. Addict Biol 7: 37 – 43.
dc.identifier.citedreferenceHartmann‐Boyce J, Stead LF, Cahill K, Lancaster T ( 2014 ) Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction 109: 1414 – 1425.
dc.identifier.citedreferenceHeatherton TF, Kozlowski LT, Frecker RC, Fagerström KO ( 1991 ) The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86: 1119 – 1127.
dc.identifier.citedreferenceHughes JR, Keely JP, Niaura RS, Ossip‐Klein DJ, Richmond RL, Swan GE ( 2003 ) Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 5: 13 – 25.
dc.identifier.citedreferenceHumfleet G, Munoz R, Sees K, Reus V, Hall S ( 1999 ) History of alcohol or drug problems, current use of alcohol or marijuana, and success in quitting smoking. Addict Behav 24: 149 – 154.
dc.identifier.citedreferenceJackson KJ, Jackson A, Carroll FI, Damaj MI ( 2015 ) Effects of orally‐bioavailable short‐acting kappa opioid receptor‐selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology 97: 270 – 274.
dc.identifier.citedreferenceJonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC ( 2014 ) Pharmacotherapy for adults with alcohol use disorders in outpatient settings a systematic review and meta‐analysis. JAMA 311: 1889 – 1900.
dc.identifier.citedreferenceKahler CW, Borland R, Hyland A, McKee SA, Thompson ME, Cummings KM ( 2009 ) Alcohol consumption and quitting smoking in the International Tobacco Control (ITC) Four Country Survey. Drug Alcohol Depend 100: 214 – 220.
dc.identifier.citedreferenceKahler CW, Metrik J, Lachance HR, Ramsey SE, Abrams DB, Monti PM, Brown RA ( 2008 ) Addressing heavy drinking in smoking cessation treatment: a randomized clinical trial. J Consult Clin Psychol 76: 852 – 862.
dc.identifier.citedreferenceKahler CW, Spillane NS, Metrik J ( 2010 ) Alcohol use and initial smoking lapses among heavy drinkers in smoking cessation treatment. Nicotine Tob Res 12: 781 – 785.
dc.identifier.citedreferenceKing AC, Cao D, O’Malley SS, Kranzler HR, Cai X, Dewit H, Matthews AK, Stachoviak RJ ( 2012 ) Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine‐dependent men and women. J Clin Psychopharmacol 32: 630 – 636.
dc.identifier.citedreferenceKing AC, Meyer PJ ( 2000 ) Naltrexone alteration of acute smoking response in nicotine‐dependent subjects. Pharmacol Biochem Behav 66: 563 – 572.
dc.identifier.citedreferenceKranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, Feinn R ( 2003 ) Targeted naltrexone for early problem drinkers. J Clin Psychopharmacol 23: 294 – 304.
dc.identifier.citedreferenceLeeman RF, McKee SA, Toll BA, Krishnan‐Sarin S, Cooney JL, Makuch RW, O’Malley SS ( 2008 ) Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder. Nicotine Tob Res 10: 1793 – 1809.
dc.identifier.citedreferenceLevine J, Schooler NR ( 1986 ) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343 – 381.
dc.identifier.citedreferenceLitten RZ, Castle IJ, Falk D, Ryan M, Fertig J, Chen CM, Yi HY ( 2013 ) The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res 37: 2128 – 2137.
dc.identifier.citedreferenceMcKee SA, Falba T, O’Malley SS, Sindelar J, O’Connor PG ( 2007 ) Smoking status as a clinical indicator for alcohol misuse in US adults. Arch Intern Med 167: 716 – 721.
dc.identifier.citedreferenceMeyerhoff DJ, Tizabi Y, Staley JK, Durazzo TC, Glass JM, Nixon SJ ( 2006 ) Smoking comorbidity in alcoholism: neurobiological and neurocognitive consequences. Alcohol Clin Exp Res 30: 253 – 264.
dc.identifier.citedreferenceMiller W, Rollnick S ( 2012 ) Motivational Interviewing: Helping People Change. The Guildford Press, New York, NY.
dc.identifier.citedreferenceMooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK ( 2016 ) Bupropion and naltrexone for smoking cessation: a double‐blind randomized placebo‐controlled clinical trial. Clin Pharmacol Ther 100: 344 – 352.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acer13396.pdf
Size:
244.1KB
Format:
PDF
View/Open
Name:
acer13396_am.pdf
Size:
208.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.